Angiodynamics INC 10-K annual reports

AngioDynamics files an amended annual report to include XBRL tagging, highlighting a 9.5% revenue increase to $320.2 million for fiscal year 2026, alongside a widened net loss of $36.7 million.

AngioDynamics, Inc. has filed an amended annual report (10-K/A) to include previously omitted Part III information, focusing on corporate governance, executive compensation, and security ownership, while also detailing fiscal year 2026 performance and outlook.

AngioDynamics, Inc. announced its fiscal year 2026 results, highlighting a 9.5% increase in net sales driven by its Med Tech segment, while navigating a net loss and implementing strategic restructuring initiatives.

AngioDynamics, a medical technology company, reported a significant reduction in net loss and an increase in gross margin for fiscal year 2025, driven by strong growth in its Med Tech segment and strategic divestitures, despite an overall revenue decline.

AngioDynamics' 2024 annual report highlights a strategic shift towards outsourcing manufacturing and focusing on high-growth Med Tech products, alongside significant financial impacts from divestitures and restructuring.